AUSTRALIAN drug development
company Avexa has dropped its
HIV program after it failed to
secure a manufacturer to market its
apricitabine antiviral therapy for the
treatment of drug resistant HIV.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 11 May 10 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 May 10
LEADING pharmacy, consumer and Federal agencies want to see better use of existing funding and leverage digital health resources to improve quality use of medicines, discussions at the Medicines Safety Forum in Canberra revealed.